These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 22100258)

  • 1. Synthesis, in silico, and in vitro studies of novel dopamine D
    Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Substituted
    Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
    Molecules; 2021 May; 26(11):. PubMed ID: 34073405
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery of potent dual ligands for dopamine D4 and σ1 receptors.
    Levoin N; Murthy AVR; Narendar V; Kumar NS; Aparna P; Bhavani AKD; Reddy CR; Mosset P; Grée R
    Bioorg Med Chem; 2022 Sep; 69():116851. PubMed ID: 35753263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D
    Kim HY; Lee JY; Hsieh CJ; Taylor M; Luedtke RR; Mach RH
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homobivalent Dopamine D
    Ullmann T; Gienger M; Budzinski J; Hellmann J; Hübner H; Gmeiner P; Weikert D
    ACS Chem Biol; 2021 Feb; 16(2):371-379. PubMed ID: 33435665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent ligands promote endosomal trafficking of the dopamine D3 receptor-neurotensin receptor 1 heterodimer.
    Budzinski J; Maschauer S; Kobayashi H; Couvineau P; Vogt H; Gmeiner P; Roggenhofer A; Prante O; Bouvier M; Weikert D
    Commun Biol; 2021 Sep; 4(1):1062. PubMed ID: 34508168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.
    Newman AH; Battiti FO; Bonifazi A
    J Med Chem; 2020 Mar; 63(5):1779-1797. PubMed ID: 31499001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update on Non-CB
    Morales P; Reggio PH
    Cannabis Cannabinoid Res; 2017; 2(1):265-273. PubMed ID: 29098189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease.
    Borroto-Escuela DO; Carlsson J; Ambrogini P; Narváez M; Wydra K; Tarakanov AO; Li X; Millón C; Ferraro L; Cuppini R; Tanganelli S; Liu F; Filip M; Diaz-Cabiale Z; Fuxe K
    Front Cell Neurosci; 2017; 11():37. PubMed ID: 28270751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics.
    Kaczor AA; Jörg M; Capuano B
    J Mol Model; 2016 Sep; 22(9):203. PubMed ID: 27491852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of bivalent ligands against A(1)-D(1) receptor heteromers.
    Shen J; Zhang L; Song WL; Meng T; Wang X; Chen L; Feng LY; Xu YC; Shen JK
    Acta Pharmacol Sin; 2013 Mar; 34(3):441-52. PubMed ID: 23334237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.
    Gogoi S; Biswas S; Modi G; Antonio T; Reith ME; Dutta AK
    ACS Med Chem Lett; 2012 Oct; 3(12):991-996. PubMed ID: 23275802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor signaling and current and future antipsychotic drugs.
    Boyd KN; Mailman RB
    Handb Exp Pharmacol; 2012; (212):53-86. PubMed ID: 23129328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent molecular probes for dopamine D2-like receptors.
    Huber D; Löber S; Hübner H; Gmeiner P
    Bioorg Med Chem; 2012 Jan; 20(1):455-66. PubMed ID: 22100258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.
    Ehrlich K; Götz A; Bollinger S; Tschammer N; Bettinetti L; Härterich S; Hübner H; Lanig H; Gmeiner P
    J Med Chem; 2009 Aug; 52(15):4923-35. PubMed ID: 19606869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a bivalent dopamine D₂ receptor agonist.
    Kühhorn J; Götz A; Hübner H; Thompson D; Whistler J; Gmeiner P
    J Med Chem; 2011 Nov; 54(22):7911-9. PubMed ID: 21999579
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.